MetaCap

MapLight Therapeutics Inc. (MPLT)

NASDAQ: MPLTHealth CareBiotechnology: Pharmaceutical PreparationsUSD

5.94-0.48 (-7.48%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

MPLT stock chart

Technical analysis

Key statistics

All statistics
Market cap
$330.12M
EPS (TTM)
-$6.07
52-week range
5.93 – 40.43
Day range
5.93 – 6.48
Volume / Avg
357.94K / 458.71K
Beta
—
Next earnings
Dec 3, 2026

52-week range

$5.93$40.43

MPLT stock today

MapLight Therapeutics (MPLT) closed at $5.94 on Nov 20, down 7.48% (-$0.48), versus the S&P 500's 3.70% decline. Shares are 85.3% below their 52-week high of $40.43, set on Jul 10, 2026 and 0.3% above the 52-week low of $5.93, near the bottom of the past year's range. MPLT is down 66.2% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 57.5%.

MapLight Therapeutics has posted a net loss over the last twelve months (EPS of -$6.07), so its P/E ratio is not meaningful. The company is scheduled to report Sep/2026 results on Dec 3; analysts expect EPS of -$1.22.

Summary generated from market data by MetaCap's automated system. Methodology

About MapLight Therapeutics

Company profile

MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders. The company's products include ML-007C-MA, a fixed-dose combination of an M 1 /M 4 muscarinic agonist for the treatment of schizophrenia and Alzheimer's disease psychosis; ML-004 for the treatment of social communication deficit and/or irritability in autism spectrum disorder; ML-021 for the treatment of motor deficits in Parkinson's disease; ML-055 for the treatment of neuropsychiatric conditions; and ML-009, a G-protein-coupled receptor 52 positive allosteric modulator for the treatment of hyperactivity, impulsivity and agitation-related disorders.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Christopher A. Kroeger M.B.A., M.D., Ph.D.
Headquarters
Redwood City, CA
Employees
133
IPO year
2025

Financial highlights

Full financials

MapLight Therapeutics reported a net loss of $161.2 million, compared with a loss of $77.6 million a year earlier. Diluted earnings per share came in at -$18.56.

MapLight Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024
Revenue——
Growth——
Net income$-161.15M$-77.58M
EPS (diluted)$-18.56$-105.38

Analyst forecast

Forecast

Consensus (15 analysts)

strong_buy

Avg. price target

$26.15+340.24%

  • Strong buy 1
  • Buy 11
  • Hold 3
  • Sell 0
  • Strong sell 0

Target range

Low $13.00High $43.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Next report
Dec 3, 2026
EPS estimate
$-1.22
Last reported (Sep/2026)
Dec 3, 2026
EPS actual vs est.
$-0.97 vs $-1.22
Surprise
+20.49%

MPLT news

All MPLT news

MapLight Therapeutics peers

Health Care sector
MPLT peer companies
CompanyPrice% ChgMarket capCompare
INOInovio Pharmaceuticals Inc.1.76+2.92%$329.66Mvs MPLT
LRMRLarimar Therapeutics Inc.3.14-2.48%$328.55Mvs MPLT
CTNMContineum Therapeutics Inc. Class A8.68-3.98%$340.83Mvs MPLT
AVIRAtea Pharmaceuticals Inc.3.96+0.76%$318.00Mvs MPLT
PEPGPepGen Inc.3.78-3.82%$356.31Mvs MPLT
ASPEAspen Neuroscience Inc.12.42+0.24%$361.16Mvs MPLT
SPRYARS Pharmaceuticals Inc.2.96-11.90%$297.56Mvs MPLT
PBYIPuma Biotechnology Inc7.05-0.98%$364.47Mvs MPLT

Indexes, lists and sector

MapLight Therapeutics stock FAQ

What is MapLight Therapeutics's stock price today?

MPLT last traded at $5.94 as of Nov 20, 4:00 PM EST, down 7.48% on the day. Prices are delayed at least 15 minutes.

When is MapLight Therapeutics's next earnings date?

MapLight Therapeutics is expected to report earnings on Thursday, December 3, 2026. Analysts expect EPS of $-1.22.

Who is MapLight Therapeutics's CEO?

Dr. Christopher A. Kroeger M.B.A., M.D., Ph.D. is the chief executive officer of MapLight Therapeutics Inc., which has about 133 employees.

What is the MPLT 52-week high?

The 52-week high for MPLT is $40.43 and the 52-week low is $5.93. The stock is currently 85.3% below its high.

Compare MPLT